While combination therapy with PD-1/L1 and CTLA-4 inhibitors has proven effective in some cancers, bsAbs may offer improved PK, reduced systemic toxicity, and greater tumor-specific immune modulation [191]. This evidence concerns the gene CTLA4 and cancer.